Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy

被引:1
|
作者
Derosa G. [1 ,4 ]
Cicero A.F.G. [2 ]
D'Angelo A. [1 ]
Tinelli C. [3 ]
Ciccarelli L. [1 ]
Piccinni M.N. [1 ]
Pricolo F. [1 ]
Salvadeo S. [1 ]
Montagna L. [1 ]
Fogari E. [1 ]
Gravina A. [1 ]
Ferrari I. [1 ]
Galli S. [1 ]
Paniga S. [1 ]
Fogari R. [1 ]
机构
[1] Department of Internal Medicine and Therapeutics, University of Pavia, Pavia
[2] 'D. Campanacci' Department of Clinical Medicine and Applied Biotechnology, 'G. Descovich' Atherosclerosis Study Center, University of Bologna, Bologna
[3] Biometric Unit, IRCCS Policlinico S. Matteo, Pavia
[4] Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Piazzale C. Golgi
关键词
Hypertensive Patient; Felodipine; Antihypertensive Treatment; Doxazosin; Fast Plasma Insulin;
D O I
10.2165/00151642-200613020-00002
中图分类号
学科分类号
摘要
Background: There are conflicting data in the literature regarding both the expression pattern of the vascular metalloproteinase (MMP) system and its tissue inhibitors (TIMPs) in human hypertension and the effect of antihypertensive drugs in modifying the MMP/TIMP system. This study was designed to test the hypothesis that MMP-2, MMP-9 and TIMP-1 are altered in hypertension reflecting alterations in extracellular matrix turnover. Moreover, the aim of the study was to assess whether chronic antihypertensive treatment with doxazosin would normalise these alterations. Materials and results: We measured plasma levels and activities of MMP-2, MMP-9 and TIMP-1 in 44 hypertensive patients before and after 4 months of doxazosin treatment. MMP-2 levels and activity were significantly lower in the hypertensive group after treatment (p < 0.0001) compared with respective values before treatment. Significant decrease was also observed for MMP-9 level and activity (p < 0.0001) and for TIMP-1 (p < 0.0001) in hypertensive patients after antihypertensive treatment. Conclusions: Plasma levels and activities of MMP-2, MMP-9 and TIMP-1 are decreased in hypertensive patients after treatment compared with respective values before treatment. This may demonstrate that antihypertensive drugs modify the MMP/TIMP system, contributing to the mechanisms of vascular remodelling. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:47 / 52
页数:5
相关论文
共 50 条
  • [1] Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension
    Derosa, Giuseppe
    D'Angelo, Angela
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Salvadeo, Sibilla
    Montagna, Lorenza
    Gravina, Alessia
    Ferrari, Ilaria
    Galli, Simona
    Paniga, Sonia
    Tinelli, Carmine
    Cicero, Arrigo F. G.
    [J]. ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2006, 13 (03): : 227 - 231
  • [2] Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2
    Zhou Shao-fei
    Hu San-yuan
    Ma Lei
    Miao Lei
    Mao Wei-zheng
    [J]. CHINESE MEDICAL JOURNAL, 2013, 126 (10) : 1925 - 1929
  • [3] Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects
    Derosa, Giuseppe
    D'Angelo, Angela
    Tinelli, Carmine
    Salvadeo, Sibillaa. T.
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Montagna, Lorenza
    Ghelfi, Morena
    Ferrari, Ilaria
    Gravina, Alessia
    Cicero, Arrigo F. G.
    [J]. DIABETES, 2006, 55 : A154 - A154
  • [4] Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver
    Liu, HL
    Li, XH
    Wang, DY
    Yang, SP
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2000, 6 (06) : 881 - 884
  • [5] Matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in sera and urine of patients with renal carcinoma
    Di Carlo, Angelina
    [J]. ONCOLOGY LETTERS, 2014, 7 (03) : 621 - 626
  • [6] Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver
    Hai Lin Liu Xuan Hai Li Dan Yi Wang Shao Ping Yang Department of Gastroenterology and Hepatology
    [J]. World Journal of Gastroenterology, 2000, 6 (06) : 881 - 884
  • [7] Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure
    George, J
    Patal, S
    Wexler, D
    Roth, A
    Sheps, D
    Keren, G
    [J]. AMERICAN HEART JOURNAL, 2005, 150 (03) : 484 - 487
  • [8] The content of matrix metalloproteinase-1,-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with bronchial asthma and obesity
    Kachkovska, V. V.
    Prystupa, L. N.
    [J]. PATHOLOGIA, 2023, 20 (03): : 238 - 242
  • [9] Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
    Zhang, Yongxiang
    Li, Yuechuan
    Ye, Zhen
    Ma, Hui
    [J]. MEDICAL SCIENCE MONITOR, 2020, 26 : e925278
  • [10] Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event
    Derosa, Giuseppe
    D'Angelo, Angela
    Tinelli, Carmine
    Scalise, Filippo
    Salvadeo, Sibilla A. T.
    Carelli, Leonardi
    Piccinni, Mario N.
    Pricolo, Fabio
    Montagna, Lorenza
    Ghelfi, Morena
    Gravina, Alessia
    Ferrari, Ilaria
    Cicero, Arrigo F. G.
    [J]. DIABETES, 2006, 55 : A496 - A496